Want to see CPRX full AI Analyst Report?
CPRX Stock Chart & Stats
$26.26
-$0.35(-1.79%)
At close: 4:00 PM EST
$26.26
-$0.35(-1.79%)
Day’s Range― - ―
52-Week Range$19.05 - $32.56
Previous CloseN/A
Volume328.11K
Average Volume (3M)2.28M
Market Cap
$3.85B
Enterprise Value$2.39K
Total Cash (Recent Filing)$755.86M
Total Debt (Recent Filing)$2.68M
Price to Earnings (P/E)17.5
Beta0.69
Next Earnings
Aug 12, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.80
Shares Outstanding122,417,460
10 Day Avg. Volume3,009,295
30 Day Avg. Volume2,279,738
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)2.99
Price to Sales (P/S)4.85
P/FCF Ratio13.68
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$32.10Price Target Upside22.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)1.95
Revenue Forecast (FY)$633.88M
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsSustained high gross and net margins indicate durable pricing power in specialty rare-disease drugs and efficient cost structure. Strong margins support reinvestment in R&D and patient support, fund potential M&A, and underpin long-term cash generation even if top-line growth slows.
Exceptionally Conservative Balance SheetMinimal debt and a growing equity base provide financial flexibility to fund product launches, absorb revenue volatility common in orphan drugs, and pursue strategic investments without refinancing risk. This conservatism reduces solvency risk and preserves optionality over the medium term.
Extended Firdapse Exclusivity (Patent Settlement)A settlement that delays generic entry to 2035 materially extends predictable cash flows from Firdapse, preserving a core revenue stream for years. That exclusivity horizon improves long-term revenue visibility and supports stable margins and internal investment planning.
Bears Say
Slowing Revenue GrowthRevenue growth has decelerated to near-flat TTM levels after prior rapid expansion, signaling that market penetration or product lifecycle gains may be exhausted. Sustaining return-on-equity and funding new initiatives will be harder without resumed top-line momentum or new product commercialization.
Recent Decline In Free Cash Flow GrowthAlthough absolute operating and free cash flow remain strong, the negative growth trend weakens the trajectory for internally funding R&D, launches, or bolt-on deals. If FCF volatility persists, management may face trade-offs between investment, dividends, or reliance on external financing.
Change-of-Control And Strategic UncertaintyAn imminent acquisition introduces durable strategic uncertainty: integration choices, reprioritization of programs, and potential restructuring could alter commercialization focus and capital allocation. For stakeholders, the loss of independent strategy may change long-term product prioritization and execution risk.
Catalyst Pharma News
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $19.05 and its highest was $32.56 in the past 12 months.
What is Catalyst Pharma’s market cap?
Catalyst Pharma’s market cap is $3.85B.
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is Aug 12, 2026 which is in 23 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on May 11, 2026. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.475 by $0.025.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is 0.46.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 122,417,460 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.5 in its last earnings report, beating expectations of $0.475. Following the earnings report the stock price went down -0.032%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Currently, no hedge funds are holding shares in CPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Catalyst Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.10 (22.24% Upside)
$32.10 (22.24% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 677.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.1%
Last 30 Days ▼ 11.4%
Last 30 Days ▼ 11.4%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
26.27%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
CPRX Stock 12 Month Forecast
Average Price Target
$32.10
▲(22.24% Upside)
Technical Analysis
Ownership Overview
― Insiders
19.68% Mutual Funds
0.23% Other Institutional Investors
74.22% Public Companies and Individual Investors